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In contrast to the decline in FEV1, the behavior of dynamic hyperinflation (DH) over time is
unknown in patients with COPD. Metronome-paced hyperventilation (MPH) is a simple appli-
cable surrogate for exercise to detect DH.
Objective: To evaluate changes in MPH-induced DH during two years follow-up in mild-to-
severe COPD patients. Additionally, influence of smoking status on DH and the relation
between DH and other lung function parameters were assessed.
Methods: Patients were recruited from a randomized controlled trial conducted in general
practice. Measurements of lung function and DH were performed at baseline and after 12
and 24 months. DH was assessed by MPH with breathing frequency set at twice the baseline
rate. Change in inspiratory capacity after MPH was used to reflect change in end-expiratory
lung volume and therefore DH, presuming constant total lung capacity.
Results: During follow-up, 68 patients completed all measurements. DH increased by 0.23
 0.06 L (p 0.001). No significant changes in FEV1 %pred were seen. Smokers had lower
FEV1 and a more rapid decline than non-smokers. DH in smokers increased more over time
compared to non-smokers. The amount of DH correlated positively with resting inspiratory
capacity.
Conclusion: After two years, a significant increase in MPH-induced DH in COPD patients was
demonstrated, which was not accompanied by a decline in FEV1. It might be that DH is a sensi-
tive measure to track consequences of changes in airflow obstruction.
ª 2010 Elsevier Ltd. All rights reserved.of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nij-
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive disease with major impact on individual patients’
quality of life. According to ATS/ERS consensus statements,
forced expiratory volume in 1 s (FEV1) is used worldwide to
diagnose and stage COPD.1 FEV1 and the rate of its decline
are both predictors of mortality.2,3 However, this param-
eter of disease progression fails to be a reliable predictor of
patient centred outcomes like exercise tolerance, dysp-
noea or health related quality of life.4 In these outcomes,
changes in operating lung volumes appear to play a more
important role.5 The origin of these changes in lung
volumes is dynamic hyperinflation (DH), which is defined as
a transient increase in end-expiratory lung volume (EELV) as
a result of increasing ventilation with concomitant expira-
tory flow limitation. In contrast to the decline in FEV1 over
time, reflecting the progression in disease, the behavior of
dynamic lung volumes over time is unknown.
One explanation for this lack of information might be that
measurements of DH during exercise are quite time
consuming.DH is commonlyestimatedbymeasuring change in
inspiratory capacity (IC) during exercise, which reflects
change in EELV. Gelb et al. compared DH after incremental
cycle ergometry and metronome-paced hyperventilation
(MPH) in COPD patients.6 IC was measured at rest and imme-
diately after 20 s MPH with breathing frequency set at twice
the resting rate.6 The change in IC after MPH was comparable
to the change in IC after incremental cycle ergometry.
Therefore,MPH isa simpleapplicable surrogate forexercise to
detect DH. This offers a practical solution to study changes in
DH over time. The purpose of the present study was to eval-
uatechanges inMPH-inducedDHduring two years of follow-up
in patients with COPD. In addition, the influence of smoking
status on DH was explored and the relation between DH and
other lung function parameters was assessed.
Methods
Subjects
Patients were recruited from a randomized controlled trial
comparing three different modes of COPD disease manage-
ment in general practice, conducted by the Department of
Primary and Community Care of the Radboud University
Nijmegen Medical Centre. Details of this trial are described
at http://ClinicalTrials.gov, identifier NCT00128765.
Inclusion criteria were mild-to-severe COPD according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) classification1 and age 35 years. Exclusion criteria
were GOLD stage IV, treatment by a chest physician and
severe co-morbidity with reduced life expectancy. An
additional exclusion criterion for the present study was the
inability to visit our pulmonary function unit. This study was
approved by the local medical ethics committee. All
participants gave written informed consent.
Study design
In the present study, IC measurements and spirometry were
the primary outcomes. Measurements were performed atbaseline and after 12 and 24 months. Patients were free of
exacerbation during testing. Prescriptions for pulmonary
medication during the study were extracted from the
general practitioners’ medical records.
Spirometry and IC measurements
Patients were instructed to continue their usual medication,
but to withhold short-acting b2-agonists and/or anti-cholin-
ergics for 6 and 8 h respectively and long-acting b2-agonists
and/or anti-cholinergics for 12 and 24 h respectively prior to
testing. Pulmonary function was measured using a spirometer
(Masterlab, Jaeger, Wu¨rzburg, Germany) according to the
guidelines of the ATS/ERS.7 IC maneuvers were performed
before and immediately after 20 s MPH with breathing
frequency set at twice the current resting rate.6 Patientswere
instructed to take a deep breath in after normal exhalation
and encouraged to inspire maximally (to the total lung
capacity (TLC)). During MPH, patients were encouraged to
maintain a tidal volume (VT) equal to resting VT. Performance
of the testwasmonitoredbythe real-timedisplayofbreathing
volumes. Any inconsistency in the last breath preceding the IC
was manually corrected to obtain a true EELV.8
Repeatability of the IC’s has been tested in a subgroup.
In 18 patients, the mean coefficients of variation of resting
IC (ICrest) and IC after MPH (ICMPH) were 2.6 1.8% and
3.3 3.1% respectively.
Spirometry and IC maneuvers were repeated after
administration of 80 mg ipratropium/400 mg salbutamol. If
not stated otherwise, post-bronchodilation values are pre-
sented in the results.
Predicted ICrest was calculated as predicted TLC minus
the predicted functional residual capacity. Change in IC
(DIC: ICMPH ICrest) was used to reflect DH, presuming
constant TLC.9,10 Inspiratory reserve volume (IRV) was
calculated as IC VT. Minute ventilation was calculated by
breathing frequency VT.Statistical analysis
Data are expressed as mean se. Changes in lung function
parameters and DH over time were analysed with general
linear models for repeated measures (two-factor mixed
design: time and group). Post hoc analyses were performed
with Bonferroni (time) and Scheffe´ (group) corrections for
multiple comparisons. Differences between pre- and post-
bronchodilation values were tested with a two-way
repeated measures design. Pearson correlation coefficient
was used to evaluate associations between lung function
parameters and DH. Statistical significance was set at
p< 0.05. Data were analysed with SPSS, version 16.0 (SPSS,
Chicago, IL).Results
Study population
After initial screening, 124 patients were included in the
current study. During two years of follow-up, 68 patients
completed all measurements (Fig. 1). Reasons for drop-out
Figure 1 Overview of the number of participants initially included and those remaining after two years.
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occurrence of co-morbidity with reduced life expectancy
(nZ 3), death (nZ 4), software problems (nZ 9) or
unknown (nZ 25).
Patient characteristics
Sixty-eight patients (GOLD I nZ 8, GOLD II nZ 47, GOLD III
nZ 13) had complete follow-up. Seventy-two percent of
the study population was male. Mean age at baseline was
64 1 years and body mass index was 26.4 0.5 kg/m2.
Patients who were excluded because of missing data or
withdrawal had similar baseline characteristics as those with
complete data sets (data not shown). Twenty-nine percent
used any long-acting bronchodilator and 16% used tiotropium.
Mean post-bronchodilation FEV1 at baseline was 66% of pre-
dicted. Mean MPH-induced DIC at baseline was 0.44 L.
Differences between management groups during
follow-up
Patient characteristics, lung function parameters and DH
were similar in the disease management groups at baselineTable 1A Pre-bronchodilation follow-up lung function paramet
Baseline
FEV1 (L) 1.67 0.06
FEV1 (%pred) 57 2
ICrest (L) 2.74 0.08
ICrest (%pred) 98 2
DIC (L) 0.51 0.04
IRVMPH (L) 1.31 0.07
VeMPH (L/min) 26.0 1.1
DVe (L/min) 13.8 0.8
DIC/DVe (L/L/min) 0.05 0.01
All values are mean se.
Abbreviations: FEV1: forced expiratory volume in 1 s; IC: inspirator
metronome-paced hyperventilation; Ve: ventilation.
*: p< 0.05 versus baseline; **: p< 0.05 versus 12 months.and during two year follow-up. In addition, prescription of
long-acting bronchodilation and drop-out rate were
comparable between the management groups. Therefore,
follow-up analyses are described without separate group
values.
Course of lung function parameters and dynamic
hyperinflation
Pre- and post-bronchodilation results are presented in
Table 1A and B respectively. Post-bronchodilation values of
FEV1 (L and %pred), ICrest (L and %pred), IRV after MPH,
ventilation after MPH and change in ventilation from rest to
MPH (Dventilation) were significantly greater than pre-
bronchodilation values at all time points (all p< 0.001).
The rate of DH (DIC/Dventilation) was significantly smaller
after bronchodilation (p< 0.001).
During the two years follow-up, there was no significant
decrease in post-bronchodilation FEV1 %pred, although
absolute FEV1 slightly decreased (0.06 0.02 L, 95%CI
0.00e0.12 L; p< 0.05) (Table 1B). ICrest improved signifi-
cantly during follow-up with 7 2%pred (95%CI 1.9e11.7 %
pred; p< 0.01).ers.
12 months 24 months
1.63 0.06 1.61 0.07*
56 2 56 2
2.72 0.08 2.85 0.09
98 2 103 2
0.61 0.04 0.62 0.04
1.18 0.05 1.29 0.06**
27.5 1.3 28.7 1.1*
14.2 1.1 12.7 0.9
0.07 0.01 0.09 0.02
y capacity; D: MPH-rest; IRV: inspiratory reserve volume; MPH:
Table 1B Post-bronchodilation follow-up lung function parameters.
Baseline 12 months 24 months
FEV1 (L) 1.92 0.07 1.87 0.07 1.86 0.07*
FEV1 (%pred) 66 2 64 2 65 2
ICrest (L) 2.93 0.08 2.96 0.09 3.09 0.09*
ICrest (%pred) 105 2 107 3 112 2**
DIC (L) 0.44 0.04 0.49 0.04 0.66 0.05***&
IRVMPH (L) 1.53 0.07 1.47 0.07 1.41 0.06
VeMPH (L/min) 28.6 1.4 30.9 1.4 32.7 1.5**
DVe (L/min) 15.9 1.1 17.2 1.1 14.9 1.0
DIC/DVe (L/L/min) 0.04 0.00 0.03 0.00 0.07 0.01***&&
All values are mean se.
Abbreviations: FEV1: forced expiratory volume in 1 s; IC: inspiratory capacity; D: MPH-rest; IRV: inspiratory reserve volume; MPH:
metronome-paced hyperventilation; Ve: ventilation.
*: p< 0.05 versus baseline; **: p< 0.01 versus baseline; ***: p 0.001 versus baseline; &: p< 0.05 versus 12 months; &&: p< 0.01 versus
12 months.
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0.09e0.37 L; p 0.001) during the 2 year follow-up period
(Table 1B). VT did not change over time and breathing
frequency at rest and during MPH increased slightly from
baseline to 24 months (1 and 2 breaths/min respectively;
p< 0.05). This resulted in higher minute ventilation at 24
months (Table 1B).However, change in ventilation from rest to
MPH did not significantly differ between baseline and follow-
up measurements. Furthermore, when DIC was expressed per
change in ventilation, a higher rate of DH was shown during
follow-up. IRVafterMPHdidnotchange significantlyover time.
Sixty-three percent of the patients had at least one
prescription for any long-acting bronchodilator during the
study. These patients had lower FEV1 %pred than those whoFigure 2 A: FEV1 %pred at baseline, 12 and 24 months for
smokers and non-smokers. B: DIC after MPH at baseline, 12 and
24 months for smokers and non-smokers.did not have a long-acting bronchodilator prescription
(p< 0.05), but the rate of decline was equal. ICrest was
comparable between these groups. The 40% of patients
receiving at least one prescription for tiotropium, also had
smaller FEV1 %pred (p< 0.01) than those who were not
prescribed tiotropium. FEV1 %pred rate of decline and ICrest
were similar among these groups.
Influence of smoking status
The group of current smokers (nZ 27) had a different gender
distribution compared to current non-smokers (nZ 41) (56
and 83% male respectively; p< 0.001). Furthermore,
smokers were younger than non-smokers (age 61 1 and
66 1 years respectively; p< 0.05). Therefore, only relative
measures were used for comparisons between these groups.
Smokers had smaller FEV1 values and a more rapid decline
(Fig. 2A). Resting IC at baseline was 99 4%pred in smokers
and 109 3%pred in non-smokers (p< 0.001), but improved
equally in both groups. Ventilation and change in ventilation
from rest to MPH were similar in the groups. DH in smokers
increased more over time (Fig. 2B). This did not result in
a significant difference in IRV between the groups.
Correlations
FEV1 correlated with ICrest at baseline, 12 and 24 months
(rZ 0.53, 0.49, 0.65 respectively; all p< 0.001) (Fig. 3).Figure 3 Correlation between FEV1 and ICrest at 24 months.
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respectively; all p< 0.001) and IRV after MPH (rZ 0.59,
0.59, 0.65 respectively; all p< 0.001). Thus, larger ICrest
was associated with more DH, but with greater IRV after
MPH. No correlation was found between FEV1 and DIC.
However, FEV1 %pred did correlate with the rate of DH
(rZ 0.36, 0.42 at baseline and 12 months; p< 0.01 and
<0.001 respectively).
In the smokers subgroup a correlation between FEV1 %
pred and DIC at baseline and 12 months was found (rZ 0.43
and rZ 0.54 respectively, both p< 0.05).Discussion
This is the first study describing changes in DH over time in
patients with mild-to-severe COPD. We followed 68
patients recruited from general practice for two years and
found an increase in MPH-induced DH of 0.23 L. Also, DIC/
Dventilation, the rate of DH, increased during follow-up.
Subgroup analysis revealed that smokers had a more rapid
increase of DH over time than non-smokers.
It was hypothesized that DH develops only when COPD
becomes severe.11 In our subjects, increase in DH over time
was not accompanied by a decline in FEV1 %pred. Further-
more, even our milder patients already showed DH, in line
with recent findings of occurrence of DH in mild and
moderate COPD.12,13 Together, these findings rather
contradict the hypothesis of the development of DH in the
natural history of COPD, though we recognize the fact that
three measurements in two years may be too short to
represent natural history.
The steeper increase in DH in smokers was accompanied
by a faster decline in FEV1, suggesting that in this subgroup
airflow obstruction, as reflected by FEV1, does contribute to
the level of DH. DH is a consequence of airflow limitation,
which however may not be represented entirely by FEV1. It
might be that additional parameters of flow obstruction as
derived by the appliance of negative expiratory pressure14 or
measures of peripheral obstruction better reflect airflow
limitation. DH could be a sensitive measure to express the
consequences of changes in airflow obstruction.
ICrest correlated with MPH-induced DH, which is
comparable to earlier findings in which resting IC correlated
with DH at peak exercise.15 This supports the idea that the
amount of DH might be partially determined by resting
volumes, thus, the more space the more DH. Resting IC
slightly increased during follow-up, which might be due to
increased long-acting bronchodilator use.16e18 Sixty-three
percent of the subjects had a long-acting bronchodilator
prescribed during follow-up. Although patients stopped
their long-acting b2-agonists and/or anti-cholinergics for 12
and 24 h respectively prior to measurements, there might
still be an effect on ICrest.
16e18 However, no differences in
ICrest were found between those who did and did not
receive a prescription for a long-acting bronchodilator.
Since information on the actual use of these medications is
lacking, this conclusion has to be interpreted with caution.
We cannot exclude the possibility that the small increase in
ICrest occurred due to an increase in TLC.
In our study, post-bronchodilation MPH-induced DH was
approximately 0.5 L at all time points. O’Donnell et al.demonstrated that exercise-induced DH of w0.5 L was
associated with a steep increase in dyspnoea intensity.19
This 0.5 L limit for DH was obtained in severe patients
with COPD with an IRV ofw0.5 L after exercise, which also
has been associated with a strong increase in dyspnoea.19
Change in IRV has been shown to be the best predictor of
dyspnoea after exercise and leads to neuromechanical
dissociation.20,21 A greater tolerance of DH after broncho-
dilation versus placebo19 indicates that relevant DH prob-
ably cannot be represented by a fixed amount. Probably,
DH together with decreased resting IC leads to a critically
small IRV and therefore to dyspnoea with consequent
exercise intolerance.
In our study, IRV after MPH did not reach the critical
limit of w0.5 L.19,20 This might be partially explained by
a lower VT during MPH compared to exercise. The low VT/
IC ratio after MPH (w0.4) indicates that there would have
been more room to expand VT. However, Ofir et al. have
shown that even with greater VT, IRV is preserved in milder
patients. They studied patients with comparable resting IC,
equal amounts of DH, but greater VT/IC ratios (w0.7)
during peak exercise. Despite larger VT, those subjects did
not reach the critical limit of IRV.12 This supports our idea
that the relatively large resting IC is the main reason that
a critical IRV is not reached during MPH in our population.
There are some study limitations that need to be
addressed. Our population was subject to a disease
management intervention. No differences between the
management groups in patient characteristics, and lung
function indices and MPH-induced DH over time were seen.
However, there might be an overall positive in-study effect
on lung function. Furthermore, we did not assess TLC. The
IC/TLC ratio at rest would have given an additional
description of static hyperinflation over time. Also, venti-
lation increased over time, which suggests some bias in the
increase in DH. However, change in ventilation from rest to
MPH did not alter and the rate of DH (DIC/Dventilation)
increased, which is consistent with the increase in DH.
Finally, drop-out was considerable, w40%, which
compromises generalizability of the results, but was
comparable with other COPD trials.22,23Conclusion
After a two year follow-up significant increase in MPH-
induced DH in patients with mild-to-severe COPD was
demonstrated, in the absence of change in FEV1 %pred. It
might be that DH is a sensitive measure to track conse-
quences of changes in airflow obstruction.
Future studies should be directed at elucidating factors
that determine DH and at investigating the clinical rele-
vance of DH, especially in patients with mild and moderate
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